Physician profile
Jack William Mounce
NPI 1154898666
$7,479.20
in general payments reported to CMS, 2019-2025
29 companies · $2,026 in 2025
The $2,026 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.85 · 2022: $2,104 · 2023: $2,130 · 2024: $1,161 · 2025: $2,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,894 · Travel and Lodging: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,893.92 |
| Travel and Lodging | $1,423.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,972.58 | 2022-2025 | Vanta Adaptivestim, Synchromedii, Intellis Adaptivestim |
| Relievant Medsystems, INC. | $1,628.42 | 2022-2023 | Intracept |
| Si-Bone, INC. | $1,056.84 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $511.11 | 2022-2025 | Relistor |
| Boston Scientific Corporation | $462.66 | 2023-2025 | Bionic Navigator, General - Pain Management, Wavewriter Alpha Prime 16 |
| Curonix LLC | $211.20 | 2022-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Stimwave Technologies Incorporated | $193.18 | 2022 | |
| Almatica Pharma LLC | $156.37 | 2022-2023 | Gralise, Loreev Xr |
| Merz North America, INC. | $149.21 | 2021-2022 | |
| Abbvie INC. | $147.36 | 2023-2025 | |
| Novo Nordisk INC | $122.55 | 2024 | Wegovy |
| Vertex Pharmaceuticals Incorporated | $115.00 | 2024 | |
| Lundbeck LLC | $101.46 | 2023-2025 | Vyepti |
| Protega Pharmaceutials INC | $91.27 | 2025 | Roxybond |
| Bioventus LLC | $78.30 | 2024-2025 | Durolane |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $58.02 | 2025 | Prospera |
| Amneal Pharmaceuticals LLC | $56.34 | 2023 | Lyvispah |
| Scilex Pharmaceuticals INC. | $48.47 | 2022 | |
| Spr Therapeutics, INC | $48.20 | 2023 | Sprint Pns System |
| Cvrx, INC. | $43.55 | 2021 | |
| Radius Health, INC. | $34.17 | 2024 | |
| Averitas Pharma INC. | $32.69 | 2025 | Qutenza |
| Ibsa Pharma INC. | $31.86 | 2022 | |
| Globus Medical, INC. | $29.07 | 2025 | Senza |
| Tonix Medicines, INC. | $25.16 | 2025 | Tonmya |
| Foundation Fusion Solutions, LLC | $20.17 | 2024 | |
| Valinor Pharma, LLC | $19.37 | 2024 | Movantik |
| Nevro Corp. | $19.09 | 2023 | Senza |
| Masimo Corporation | $15.53 | 2023 | Patient Safetynet System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Mounce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.